Literature DB >> 19353664

Reproducibility of cerebral phenylalanine levels in patients with phenylketonuria determined by 1H-MR spectroscopy.

R Kreis1, K Zwygart, C Boesch, J-M Nuoffer.   

Abstract

The reproducibility of metabolite content determined by MR spectroscopy (MRS) is usually at best a few percent for the prominent singlets. When studying low-concentration metabolites, like phenylalanine (Phe), where tissue content can be <100 micromol/kg, better reproducibility is paramount-particularly in view of using MRS results for potential individual treatment advice. An optimized, targeted spectroscopy method was established at 1.5T and reproducibility was established in 21 patients with phenylketonuria (PKU) where three spectra were recorded in each of three independent sessions, two of which were in immediate succession to minimize physiologic variation. Intersession variation was found to be only 7 micromol/kg Phe for back-to-back repetition of sessions, in close agreement with the variation of 16 micromol/kg observed for single spectra within a session. Analysis of variance proved the individuality of the blood/brain Phe ratio-though this ratio seems to be influenced by physiologic factors that are not stable in time. The excellent reproducibility was achieved through optimization of various factors, including signal-to-noise ratio, repositioning, and prescan calibrations, but also by enforcing as much prior information as possible (e.g., lineshape and phase from reference scans, constant prior-knowledge-locked baseline). While the application of maximum general prior knowledge is a general method to reduce fluctuations, one should remember that it may introduce systematic errors. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353664     DOI: 10.1002/mrm.21983

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  6 in total

Review 1.  New frontiers in neuroimaging applications to inborn errors of metabolism.

Authors:  Morgan J Prust; Andrea L Gropman; Natalie Hauser
Journal:  Mol Genet Metab       Date:  2011-06-30       Impact factor: 4.797

2.  Magnetic resonance spectroscopic imaging of downfield proton resonances in the human brain at 3 T.

Authors:  Michal Považan; Michael Schär; Joseph Gillen; Peter B Barker
Journal:  Magn Reson Med       Date:  2021-12-31       Impact factor: 4.668

3.  Improved Measurement of Brain Phenylalanine and Tyrosine Related to Neuropsychological Functioning in Phenylketonuria.

Authors:  Susan E Waisbren; Sanjay P Prabhu; Patricia Greenstein; Carter Petty; Donald Schomer; Vera Anastasoaie; Kalin Charette; Daniel Rodriguez; Sai Merugumala; Alexander P Lin
Journal:  JIMD Rep       Date:  2016-09-28

Review 4.  Neurometabolic diseases of childhood.

Authors:  Zoltan Patay; Susan I Blaser; Andrea Poretti; Thierry A G M Huisman
Journal:  Pediatr Radiol       Date:  2015-09-07

Review 5.  Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.

Authors:  Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow
Journal:  Dev Neuropsychol       Date:  2016-11-02       Impact factor: 2.253

6.  Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.

Authors:  Roman Trepp; Raphaela Muri; Stephanie Abgottspon; Lenka Bosanska; Michel Hochuli; Johannes Slotboom; Christian Rummel; Roland Kreis; Regula Everts
Journal:  Trials       Date:  2020-02-13       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.